Quarterly report pursuant to Section 13 or 15(d)

DERIVATIVE LIABILITY (Details Narrative)

v3.24.1.u1
DERIVATIVE LIABILITY (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Jul. 28, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Gain (Loss) on Sale of Derivatives $ 28,568 $ 0    
Derivative liability $ 10,882   $ 39,450  
Probability of increased in repayment of loan 0.00%   55.00%  
Loan Agreement [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Probability of decreased repayment of loan 10.00%   10.00%  
Loan Agreement [Member] | K2 HealthVentures LLC [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Secured debt $ 14,562,769      
Loan Agreement [Member] | K2 HealthVentures LLC [Member] | Share-based Payment Arrangement, Tranche One [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Secured debt       $ 20,000,000
derivative liability Level 3 [Member] | K2 HealthVentures LLC [Member]        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Gain (Loss) on Sale of Derivatives 28,568      
Derivative liability $ 10,882